23andMe’s consumer pharmacogenetics report no longer requires follow-up testing for certain medications

While the company’s new 510(k) cuts down some of the burden, consumers are still advised to consult their healthcare provider before making any changes to their treatments.

Leave a Reply

Your email address will not be published.